Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | POLR1A | O95602 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256577 | 1.00 | MALT1 (0.37) | MALT1IL1BPOLR1ASLC6A4PDK1 | |
| SCHEMBL22010188 | 1.00 | MALT1 (0.37) | MALT1IL1BPOLR1ASLC6A4PDK1 | |
| SCHEMBL24634126 | 0.81 | MALT1 (0.36) | MALT1IL1BPOLR1ASLC6A4PDK1 | |
| SCHEMBL18233614 | 0.79 | MALT1 (0.35) | MALT1IL1BPOLR1ASLC6A4PDK1 | |
| SCHEMBL15783062 | 0.78 | MALT1 (0.34) | MALT1IL1BPOLR1ASLC6A4 | |
| SCHEMBL21430682 | 0.77 | PDK1 (0.36) | PDK1PDK2PDK3 | |
| SCHEMBL30484 | 0.77 | — | — | |
| SCHEMBL13090159 | 0.77 | — | — | |
| SCHEMBL19267113 | 0.77 | — | — | |
| SCHEMBL23866592 | 0.77 | MALT1 (0.46) | MALT1IL1BPOLR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4688782-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024222842-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-10-31 | — | — | WO | disclosed |
| WO-2020001592-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USE THEREOF | 河南天晟泰丰医药科技有限公司 | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, CBR1, SRD5A1 | MALT1 463/4885IL1B 4425/4885POLR1A 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.